Next Article in Journal
Botched Ebola Vaccine Trials in Ghana: An Analysis of Discourses in the Media
Previous Article in Journal
Assessment of Vaccine Hesitancy to a COVID-19 Vaccine in Cameroonian Adults and Its Global Implication
Previous Article in Special Issue
Immune Complex Vaccine Strategies to Combat HIV-1 and Other Infectious Diseases
Open AccessReview

HIV-1 Envelope Glycosylation and the Signal Peptide

Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, New York, NY 10029, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Ralph A. Tripp
Vaccines 2021, 9(2), 176; https://doi.org/10.3390/vaccines9020176
Received: 21 January 2021 / Revised: 7 February 2021 / Accepted: 16 February 2021 / Published: 19 February 2021
(This article belongs to the Special Issue HIV Vaccine)
The RV144 trial represents the only vaccine trial to demonstrate any protective effect against HIV-1 infection. While the reason(s) for this protection are still being evaluated, it serves as justification for widespread efforts aimed at developing new, more effective HIV-1 vaccines. Advances in our knowledge of HIV-1 immunogens and host antibody responses to these immunogens are crucial to informing vaccine design. While the envelope (Env) protein is the only viral protein present on the surface of virions, it exists in a complex trimeric conformation and is decorated with an array of variable N-linked glycans, making it an important but difficult target for vaccine design. Thus far, efforts to elicit a protective humoral immune response using structural mimics of native Env trimers have been unsuccessful. Notably, the aforementioned N-linked glycans serve as a component of many of the epitopes crucial for the induction of potentially protective broadly neutralizing antibodies (bnAbs). Thus, a greater understanding of Env structural determinants, most critically Env glycosylation, will no doubt be of importance in generating effective immunogens. Recent studies have identified the HIV-1 Env signal peptide (SP) as an important contributor to Env glycosylation. Further investigation into the mechanisms by which the SP directs glycosylation will be important, both in the context of understanding HIV-1 biology and in order to inform HIV-1 vaccine design. View Full-Text
Keywords: HIV-1; HIV envelope; glycosylation; signal peptide; PNGS; broadly neutralizing antibodies; vaccine HIV-1; HIV envelope; glycosylation; signal peptide; PNGS; broadly neutralizing antibodies; vaccine
Show Figures

Figure 1

MDPI and ACS Style

Lambert, G.S.; Upadhyay, C. HIV-1 Envelope Glycosylation and the Signal Peptide. Vaccines 2021, 9, 176. https://doi.org/10.3390/vaccines9020176

AMA Style

Lambert GS, Upadhyay C. HIV-1 Envelope Glycosylation and the Signal Peptide. Vaccines. 2021; 9(2):176. https://doi.org/10.3390/vaccines9020176

Chicago/Turabian Style

Lambert, Gregory S.; Upadhyay, Chitra. 2021. "HIV-1 Envelope Glycosylation and the Signal Peptide" Vaccines 9, no. 2: 176. https://doi.org/10.3390/vaccines9020176

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop